News & Updates

Show Multimedia Only

BGF initiation after an exacerbation in COPD: Does timing matter?

06 Jun 2025 by

Findings from the MITOS EROS+CP (US) study underscore the importance of prompt initiation of budesonide/glycopyrrolate/formoterol fumarate (BGF) following an exacerbation in patients with chronic obstructive pulmonary disease (COPD).

BGF initiation after an exacerbation in COPD: Does timing matter?

06 Jun 2025

Potent KV7 potassium channel opener shows promise in MDD treatment

06 Jun 2025

The KV7 potassium channel opener azetukalner helps improve symptoms of major depressive disorder (MDD) in adults, according to the results of the proof-of-concept, phase II X-NOVA study.

Potent KV7 potassium channel opener shows promise in MDD treatment

06 Jun 2025

$Aviptadil plus phentolamine shows potential for refractory ED management$

Aviptadil plus phentolamine shows potential for refractory ED management

05 Jun 2025

Intracavernosal injection (ICI) of aviptadil with phentolamine mesylate (AvP) demonstrates efficacy in more than half of the men with refractory erectile dysfunction (ED) who participated in a recent study.

Aviptadil plus phentolamine shows potential for refractory ED management

05 Jun 2025

Cannabis abuse ups risks of erectile dysfunction, testosterone deficiency

05 Jun 2025

Dependence on or excessive use of cannabis appears to increase the risk of erectile dysfunction (ED), testosterone deficiency (TD), and phosphodiesterase-5 inhibitor (PDE5-i) prescription, reveals a study.

Cannabis abuse ups risks of erectile dysfunction, testosterone deficiency

05 Jun 2025

Atezolizumab-bevacizumab provides optimal balance between survival, QoL benefits in HCC

05 Jun 2025 by

A network meta-analysis (NMA) reports that the combination regimen comprising atezolizumab and bevacizumab appears to be better than other first-line systemic therapeutic alternatives for advanced hepatocellular carcinoma (HCC) in terms of providing a balance between overall survival (OS) benefit and quality of life (QoL) preservation.

Atezolizumab-bevacizumab provides optimal balance between survival, QoL benefits in HCC

05 Jun 2025

Amiloride noninferior to spironolactone for resistant hypertension

05 Jun 2025

In the treatment of patients with resistant hypertension, amiloride is no better or worse than spironolactone at reducing home systolic blood pressure (SBP) levels, according to a study.

Amiloride noninferior to spironolactone for resistant hypertension

05 Jun 2025

Discontinuing antipsychotics for delirium lowers risks of rehospitalization, mortality

04 Jun 2025

For older adults who received treatment with antipsychotics to manage delirium, medication discontinuation leads to better outcomes, including reduced risks of all-cause rehospitalization and mortality, compared with continued use, according to a study.

Discontinuing antipsychotics for delirium lowers risks of rehospitalization, mortality

04 Jun 2025

Phase IIb study supports lorundrostat for treatment-resistant hypertension

04 Jun 2025 by

The phase IIb Advance-HTN trial shows the blood pressure (BP)-lowering effect of lorundrostat in patients with uncontrolled and treatment-resistant hypertension (HTN).

Phase IIb study supports lorundrostat for treatment-resistant hypertension

04 Jun 2025

Residual recurrence risk high after AF-related stroke

04 Jun 2025

Approximately one in six atrial fibrillation (AF) patients who sustained a stroke experiences another one within 5 years despite receiving modern preventive therapy, according to a systematic review and meta-analysis.

Residual recurrence risk high after AF-related stroke

04 Jun 2025

Elebsiran + PEG-IFN alfa combo ENSUREs higher HBsAg loss

04 Jun 2025 by

The addition of elebsiran, an investigational small interfering ribonucleic acid (siRNA), to pegylated interferon (PEG-IFN) alfa led to a higher rate of hepatitis B surface antigen (HBsAg) loss in patients with chronic HB virus (HBV) infection compared with PEG-IFN alfa alone, according to the ENSURE study presented at EASL 2025.

Elebsiran + PEG-IFN alfa combo ENSUREs higher HBsAg loss

04 Jun 2025

News & Updates

Filter by Specialty:

Specialty:

BGF initiation after an exacerbation in COPD: Does timing matter?

BGF initiation after an exacerbation in COPD: Does timing matter?

Potent KV7 potassium channel opener shows promise in MDD treatment

Potent KV7 potassium channel opener shows promise in MDD treatment

Aviptadil plus phentolamine shows potential for refractory ED management

Aviptadil plus phentolamine shows potential for refractory ED management

Cannabis abuse ups risks of erectile dysfunction, testosterone deficiency

Cannabis abuse ups risks of erectile dysfunction, testosterone deficiency

Atezolizumab-bevacizumab provides optimal balance between survival, QoL benefits in HCC

Atezolizumab-bevacizumab provides optimal balance between survival, QoL benefits in HCC

Amiloride noninferior to spironolactone for resistant hypertension

Amiloride noninferior to spironolactone for resistant hypertension

Discontinuing antipsychotics for delirium lowers risks of rehospitalization, mortality

Discontinuing antipsychotics for delirium lowers risks of rehospitalization, mortality

Phase IIb study supports lorundrostat for treatment-resistant hypertension

Phase IIb study supports lorundrostat for treatment-resistant hypertension

Residual recurrence risk high after AF-related stroke

Residual recurrence risk high after AF-related stroke

Elebsiran + PEG-IFN alfa combo ENSUREs higher HBsAg loss

Elebsiran + PEG-IFN alfa combo ENSUREs higher HBsAg loss